French drugmakers prepare for upcoming reforms

The five major French pharmaceutical companies, grouped under G5 Santé, are preparing for the upcoming 2027 Social Security Financing Bill and the presidential election by actively engaging in policy discussions.

Health sovereignty as a key demand

G5 Santé emphasizes the importance of health sovereignty, urging that it be treated as a strategic priority in the context of the presidential election. This reflects a broader push for France to maintain control over its healthcare and pharmaceutical policies.

Studies reveal regulatory and access challenges

Two studies commissioned by G5 Santé highlight the growing regulatory burden on the pharmaceutical sector and a significant deficit in access to medicines in France. Over half of the indications approved in Europe are not readily available in the country.

Reform proposals include price freeze

The group is advocating for reform proposals, including a temporary halt on price reductions for medications. This is part of their broader strategy to ensure continued investment in medical innovation and domestic production.

G5 Santé seeks to influence presidential candidates

G5 Santé has published its findings to engage presidential candidates on the issue of access to medical innovation, aiming to shape the healthcare agenda leading up to the election. Photo credit: Sébastien Toubon.